[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"56ce6852-9361-474d-8838-60a89afe127e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475182","created_at":"2026-03-28T01:42:49.380Z","updated_at":"2026-03-28T01:42:49.380Z","phase":"Phase 1","brief_title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","source_id_and_acronym":"NCT07475182","lead_sponsor":"Hainan Cancer Hospital","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/06/2025","start_date":" 12/06/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 06/06/2028","study_completion_date":" 06/06/2028","last_update_posted":"2026-03-16"},{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"45785a07-9d38-4987-a49f-4d7f22463b54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188664","created_at":"2022-01-12T14:53:34.539Z","updated_at":"2025-02-25T14:08:34.404Z","phase":"Phase 1/2","brief_title":"Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05188664","lead_sponsor":"LaNova Australia Pty Limited","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 11/14/2023","primary_completion_date":" 11/14/2023","study_txt":" Completion: 11/14/2023","study_completion_date":" 11/14/2023","last_update_posted":"2025-02-17"},{"id":"b38928cb-8505-433c-80c6-0b0f9c9ff90b","acronym":"SHR-A1904-I-104","url":"https://clinicaltrials.gov/study/NCT05277168","created_at":"2023-01-18T16:59:24.432Z","updated_at":"2025-02-25T14:16:45.234Z","phase":"Phase 1/2","brief_title":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","source_id_and_acronym":"NCT05277168 - SHR-A1904-I-104","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e garetatug rezetecan (SHR-A1904)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 03/03/2026","primary_completion_date":" 03/03/2026","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2025-02-17"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"c806a099-ac30-4f24-bc10-a04a25d2bf23","acronym":"GEMINI-Gastric","url":"https://clinicaltrials.gov/study/NCT05702229","created_at":"2023-11-09T18:13:01.598Z","updated_at":"2025-02-25T15:13:18.164Z","phase":"Phase 2","brief_title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05702229 - GEMINI-Gastric","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/16/2023","start_date":" 01/16/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/28/2027","study_completion_date":" 01/28/2027","last_update_posted":"2025-02-13"},{"id":"e5e3ad81-9df9-4560-a791-5e9b3953d9ad","acronym":"KYM901","url":"https://clinicaltrials.gov/study/NCT04805307","created_at":"2021-03-18T11:52:24.597Z","updated_at":"2025-02-25T15:19:03.220Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","source_id_and_acronym":"NCT04805307 - KYM901","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonesitatug vedotin (AZD0901)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 04/05/2024","study_completion_date":" 04/05/2024","last_update_posted":"2025-02-12"},{"id":"6bcd23c9-26d4-4ce6-8abc-592de885dbb3","acronym":"TWINPEAK","url":"https://clinicaltrials.gov/study/NCT05482893","created_at":"2022-08-01T14:54:48.052Z","updated_at":"2025-02-25T16:18:00.073Z","phase":"Phase 1/2","brief_title":"Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)","source_id_and_acronym":"NCT05482893 - TWINPEAK","lead_sponsor":"Phanes Therapeutics","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-01-31"},{"id":"6cde80ee-7854-4076-a153-49db79a1f8a8","acronym":"8951-CL-5201","url":"https://clinicaltrials.gov/study/NCT03816163","created_at":"2021-01-18T18:51:16.508Z","updated_at":"2025-02-25T17:24:01.354Z","phase":"Phase 2","brief_title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","source_id_and_acronym":"NCT03816163 - 8951-CL-5201","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 393","initiation":"Initiation: 03/15/2019","start_date":" 03/15/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-31"},{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"91cef775-8b83-47e1-b58a-9bb196c93393","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770439","created_at":"2025-02-26T07:01:17.629Z","updated_at":"2025-02-26T07:01:17.629Z","phase":"Phase 2","brief_title":"IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06770439","lead_sponsor":"Zhejiang University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-13"},{"id":"22c483bd-8d57-4189-a689-237ee22d7ecc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06767449","created_at":"2025-02-26T07:14:39.447Z","updated_at":"2025-02-26T07:14:39.447Z","phase":"","brief_title":"Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer","source_id_and_acronym":"NCT06767449","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-09"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"e7994b16-b13b-48b5-b181-6c32d8854d0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06646783","created_at":"2025-02-26T10:15:50.233Z","updated_at":"2025-02-26T10:15:50.233Z","phase":"Phase 1","brief_title":"Phase IIT Trial of SNA014","source_id_and_acronym":"NCT06646783","lead_sponsor":"SmartNuclide Biopharma","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/20/2024","start_date":" 10/20/2024","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2024-10-17"},{"id":"2c0cee53-ab98-4b7d-ac54-95fb9c1d1159","acronym":"8951-CL-0104","url":"https://clinicaltrials.gov/study/NCT03528629","created_at":"2021-03-09T08:59:04.304Z","updated_at":"2024-07-02T16:34:25.839Z","phase":"","brief_title":"A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT03528629 - 8951-CL-0104","lead_sponsor":"Astellas Pharma Inc","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/17/2018","start_date":" 05/17/2018","primary_txt":" Primary completion: 06/09/2020","primary_completion_date":" 06/09/2020","study_txt":" Completion: 06/09/2020","study_completion_date":" 06/09/2020","last_update_posted":"2024-06-14"},{"id":"d1fb7474-3dd7-44b8-b923-5fc52d65fdb6","acronym":"CLARITY-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06219941","created_at":"2024-01-23T20:21:10.317Z","updated_at":"2024-07-02T16:34:26.279Z","phase":"Phase 2","brief_title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","source_id_and_acronym":"NCT06219941 - CLARITY-PanTumor01","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • leucovorin calcium • sonesitatug vedotin (AZD0901) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 01/19/2027","study_completion_date":" 01/19/2027","last_update_posted":"2024-06-13"},{"id":"60729fe2-47ea-41ef-9371-7af88e4f8d8f","acronym":"Spotlight","url":"https://clinicaltrials.gov/study/NCT03504397","created_at":"2021-01-18T17:15:08.157Z","updated_at":"2024-07-02T16:34:27.058Z","phase":"Phase 3","brief_title":"A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT03504397 - Spotlight","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 566","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 09/09/2022","primary_completion_date":" 09/09/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-11"},{"id":"076cd6de-9c13-4f66-953e-ae61920d0ae1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911217","created_at":"2023-06-20T14:07:52.799Z","updated_at":"2024-07-02T16:35:00.806Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","source_id_and_acronym":"NCT05911217","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-27"},{"id":"3a5fd4f8-44a2-4aeb-8b07-da3801ece8f2","acronym":"CLAUDIO-01","url":"https://clinicaltrials.gov/study/NCT05525286","created_at":"2023-11-28T16:15:12.175Z","updated_at":"2024-07-02T16:35:00.868Z","phase":"Phase 1/2","brief_title":"Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05525286 - CLAUDIO-01","lead_sponsor":"SOTIO Biotech a.s.","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOT102"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-27"},{"id":"9507ed2f-0466-4ed9-9e93-1955c7856ffd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065710","created_at":"2021-10-04T12:52:58.772Z","updated_at":"2024-07-02T16:35:01.207Z","phase":"Phase 1/2","brief_title":"A Study of ZL-1211 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05065710","lead_sponsor":"Zai Biopharmaceutical (Suzhou) Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZL-1211"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 03/09/2024","primary_completion_date":" 03/09/2024","study_txt":" Completion: 04/09/2024","study_completion_date":" 04/09/2024","last_update_posted":"2024-05-24"},{"id":"a07fe804-b24b-42e5-81ce-af1dddb29fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04400383","created_at":"2021-03-09T08:59:58.256Z","updated_at":"2024-07-02T16:35:00.974Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04400383","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • AB011"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2024-05-24"}]